Evidence map›Paper›PMID 35899182›Full record

ArticleHealth science reports2022

SARS-CoV-2 reinfection across a spectrum of immunological states.

Justine M McKittrick, Thomas W Burke, Elizabeth Petzold, Gregory D Sempowski, Thomas N Denny, Christopher R Polage, Ephraim L Tsalik, Micah T McClain

Open access · goldAbstract read
In one paragraph

Article in Health science reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Justine M McKittrickDuke University School of Medicine Durham North Carolina USA.
Thomas W BurkeCenter for Applied Genomics and Precision Medicine Duke University Durham North Carolina USA.
Elizabeth PetzoldCenter for Applied Genomics and Precision Medicine Duke University Durham North Carolina USA.
Gregory D SempowskiDuke Human Vaccine Institute Durham North Carolina USA.
Thomas N DennyDuke Human Vaccine Institute Durham North Carolina USA.
Christopher R PolageDuke University School of Medicine Durham North Carolina USA.
Ephraim L TsalikCenter for Applied Genomics and Precision Medicine Duke University Durham North Carolina USA.
Micah T McClainCenter for Applied Genomics and Precision Medicine Duke University Durham North Carolina USA.
Duke University · USPrecision for Medicine (United States) · USDurham University · GB

Funding

NIAID VIROLOGY QUALITY ASSURANCE (VQA) COVID-1975N93019C00015 · NIAID · DUKE UNIVERSITY · PI DENNY, THOMAS · 2019 to 2025
$24.4M
Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
NIAID NIH HHS 75N93019C00015NIAID NIH HHS UC6 AI058607
6 · The paper itself

Abstract

Purpose: Several cases of symptomatic reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after full recovery from a prior episode have been reported. As reinfection has become an increasingly common phenomenon, an improved understanding of the risk factors for reinfection and the character and duration of the serological responses to infection and vaccination is critical for managing the coronavirus disease 2019 (COVID-19) pandemic. Methods: We described four cases of SARS-CoV-2 reinfection in individuals representing a spectrum of healthy and immunocompromised states, including (1) a healthy 41-year-old pediatrician, (2) an immunocompromised 31-year-old with granulomatosis with polyangiitis, (3) a healthy 26-year-old pregnant woman, and (4) a 50-year-old with hypertension and hyperlipidemia. We performed confirmatory quantitative reverse transcription-polymerase chain reaction and qualitative immunoglobulin M and quantitative IgG testing on all available patient samples to confirm the presence of infection and serological response to infection. Results: Our analysis showed that patients 1 and 2, a healthy and an immunocompromised patient, both failed to mount a robust serologic response to the initial infection. In contrast, patients 3 and 4, with minimal comorbid disease, both mounted a strong serological response to their initial infection, but were still susceptible to reinfection. Conclusion: Repeat episodes of COVID-19 are capable of occurring in patients regardless of the presence of known risk factors for infection or level of serological response to infection, although this did not trigger critical illness in any instance.

Indexed as

antibodyCOVID‐19immunityreinfectionSARS‐CoV‐2

Identifiers

PMID35899182
PMCPMC9308002
OpenAlexW4286790336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.